Introduction, Radiobiology I-II, Chemistry, and Dosimetry I-II (from the Radiopharmaceutical Therapy Curriculum Series)

Introduction, Radiobiology I-II, Chemistry, and Dosimetry I-II (from the Radiopharmaceutical Therapy Curriculum Series) is organized by American Society for Radiation Oncology (ASTRO).

Course opens: 07/19/2024
Course expires: 07/04/2026

Description:
The content was originally presented and recorded on April 26, 2024 and May 24, 2024 in the Beyond the Beam: A Radiation Oncology Curriculum for Radiopharmaceutical Therapy webinar series. Beyond the Beam is a 15-hour in-depth curriculum that is designed specifically for radiation oncology residents and practicing radiation oncologists who are planning or participating in a radiopharmaceutical therapy (RPT) clinical program. The course broadly covers the topics recommended for RPT education by the International Atomic Energy Agency and the Nuclear Regulatory Commission, including physics, radiobiology, chemistry, molecular imaging, dosimetry, radiation protection, regulatory issues, quality and safety, and therapy-specific considerations of the above for PSMA-targeted agents, Ra-223, RAI, Lu-DOTATE, liver-directed RPT, and other agents.

Learning Objectives:
Upon completion of this activity, participants should be able to:

• Discuss the relevant principles of physics, chemistry and radiobiology for radiopharmaceutical therapies (RPTs).
• Identify clinical indications and therapy-specific management for RPTs that are currently approved for clinical use.
• Identify barriers and logistical steps for implementing RPT use in one's own practice.
• Explain the main steps that need to be performed for RPT dose estimation.
• Describe how dosimetry guided treatment can be used to enhance the efficacy of RPT while keeping toxicity at an acceptable level.
• Determine if the imaging requirements associated with RPT dosimetry can be reduced.
• Explain and perform BED calculations using the Medical Internal Radiation Dosimetry (MIRD) formalism or dose rate functions.
• Convert RPT doses to EBRT values, yet understand the challenges and limitations in those conversions.
• Discuss the challenges of alphaRPT dosimetry.

Topics Covered:
Introduction to Radiopharmaceutical Therapy and Curriculum Overview
—Ana Kiess, MD, PhD

Radiobiology I (PK, Biodistribution, Dose Rate, Subcellular Targeting, Molecular and Cellular Effects of Beta/Alpha, Deterministic and Stochastic Effects, Toxicities)
—Ana Kiess, MD, PhD

Chemistry of Radiopharmaceutical Therapies for Medical Use
—Freddy E. Escorcia, MD, PhD

Dosimetry I - Dosimetry Methods and Individual Dose Planning, Uncertainties
—Yuni Dewaraja, PhD

Dosimetry II / Radiobiology II - Bioeffect Modeling, Tumor Dose-Response, Toxicities, Alpha Emitters
—Robert Francois Hobbs, PhD

For more information, please see the Program tab.